Data Management And Sharing System of China National Clinical Research Center for Neurological Diseases
essential_information
2016-08-04
Published articles
Journal：stroke
Publication type: Original Contributions
IF(IF): 7.914
PMID: 27328699 Link To Pubmed Full text Download
Background And Purpose
Minor stroke and transient ischemic attack (TIA) are common disorders with high rate of subsequent disabling stroke. To identify biomarker of stroke recurrence and functional disability may be helpful for clinicians plan and adjusting therapeutic strategy. We aim to investigate the role of high-sensitive C-reactive protein (hsCRP) in predicting recurrent stroke and poor functional outcome in the Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events (CHANCE) trial.
Method
The associations of hsCRP with recurrent stroke and mRS were analyzed by using Cox proportional-hazards and logistic regression models respectively.
Conclusion
Elevated hsCRP (>3.0 mg/L) was observed in 32% of the study population. Patients with hsCRP >3 mg/L had an increased risk of recurrent stroke (adjusted hazard ratio, 1.46; 95% confidence interval, 1.08–1.98; P=0.039), ischemic stroke and combined vascular events, and poor functional outcome (adjusted odds ratio, 1.68; 95% confidence interval, 1.22–2.32; P=0.002) compared with those with hsCRP <1 mg/L within 90-day follow-up period. High hsCRP levels also independently predicted recurrent stroke during 1-year follow-up. There was no interaction of hsCRP levels with randomized antiplatelet therapy.